Patent SG-11201908159Q-A (SG)
Title: Dual magl and faah inhibitors
Inventor: GRICE CHERYL A
IPC: C07D295/205
Filed: 2018-03-12
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT Hu omit VIII °nolo H moilowo oimIE (10) International Publication Number WO 2018/169880 Al (51) International Patent Classification: A61K 31/497 (2006.01) C07D 401/02 (2006.01) C07D 295/205 (2006.01) C07D 471/10 (2006.01) (21) International Application Number: PCT/US2018/022049 (22) International Filing Date: 12 March 2018 (12.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/470,830 13 March 2017 (13.03.2017) US (71) Applicant: ABIDE THERAPEUTICS, INC. [US/US]; 10835 Road to the Cure, Suite 250, San Diego, California 92121 (US). (72) Inventors: GRICE, Cheryl A.; 10835 Road to the Cure, Suite 250, San Diego, California 92121 (US). CISAR, Justin S.; 10835 Road to the Cure, Suite 250, San Diego, California 92121 (US). DUNCAN, Katharine K.; 10835 Road to the Cure, Suite 250, San Diego, California 92121 (US). FENG, Yu; 10835 Road to the Cure, Suite 250, San Diego, California 92121 (US). WIENER, John J. M.; 10835 Road to the Cure, Suite 250, San Diego, California 92121 (US). WEBER, Olivia D.; 10835 Road to the Cure, Suite 250, San Diego, California 92121 (US). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 18/ 169880 Al (74) Agent: RIEGER, Dale L.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: DUAL MAGL AND FAAH INHIBITORS (57) : Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.